Khalid Walid Shaqdan MD, Presenter: Nothing to Disclose

Shima Aran MD, Abstract Co-Author: Nothing to Disclose

Elmira Hassanzadeh MD, Abstract Co-Author: Nothing to Disclose

Hani H. Abujudeh MD, MBA, Abstract Co-Author: Research Grant, Bracco Group Consultant, RCG HealthCare Consulting Author, Oxford University Press

• Contrast induced nephropathy (CIN) is associated with high risk of in-hospital and 1-year mortality • A survey found that less than half of physicians were aware of potential risk factors • Therefore, identifying patients at risk and taking appropriate measures are key in the prevention of contrast induced nephropathy. • The aim of this exhibit is to enhance the radiologists understanding of CIN through a literature review of the most recent guidelines and other sources  

• Background/literature review o Contrast-induced nephropathy (CIN)  Definition  Incidence and pathogenesis  Clinical features  Most recent CIN guidelines according to: • American College of Radiology • Canadian Association of Radiologist • Identifying the predisposing risk factors o Underlying health issues o Renal function markers o CIN Risk scoring system • Choice of contrast agent o Ionic and nonionic agents o Meta-analysis of benefits • Treatment and preventative strategies o Protecting renal function o Fluid Loading o Medications  N-acetylcysteine  Calcium Channel blockers  Theophylline  Other o Special considerations • Recent clinical research o Unique formulation Deferiprone o Renal Guard system • Addressing controversial issues  

http://abstract.rsna.org/uploads/2014/14007418/14007418_oeea.pdf

Shaqdan, K, Aran, S, Hassanzadeh, E, Abujudeh, H, Contrast-induced Nephropathy: Identifying the Risks and Reviewing Effective Prevention and Management Methods.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007418.html